Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

112Annual Report on Lymphatic Filariasis 2003Chapter 3 Programme implementationFigure 3.190 Outcomes and planning 2001-2005No. of IUs12108642020012002Planned pop. coverageNo. IUs20032004Figure 3.192 Geographical coverage% of at-risk population covered10075502503.0 4.6 3.4200120022005302520151050Pop. reported to haveingested drugs2003million peopleThe LF Elimination Programme is implemented by theMinistry of Health and Family Welfare. WHO providedfinancial support for social mobilization as well as technicalsupport. GSK donates albendazole to cover theat-risk population. Future partnership initiatives envisagedare with nongovernmental organizations and othersin social mobilization, disability management andcapacity-building.Figure 3.191 LF at-risk populationPopulation in millions1200 Total pop.1049 M9006003000100908088At-risk pop.454 MFigure 3.193 MDA reported coverage88.277Figure 3.194 IUs with reported coverage >65%%70100100 100608085.75020012002200360%4020Figure 3.195 Updated mapping statusTotal: 616 IUs44 IUs 311 IUs 261 IUs0200120022003Uncertain Non-endemic Endemic
NEPAL113Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF presents a health problem for the total populationof 25 million, of whom more than 22 million peopleare considered to be at risk. No national study of theprevalence and distribution of LF has been previouslyattempted, apart from a limited epidemiological surveyin semi-urban areas of the central regions of Nepal. Anevaluation of clinical manifestations of LF in sentinelsites shows a hydrocele and lymphoedema prevalence of11% and 9%, respectively.The administrative division designated as an IU is thedistrict. Mapping of LF was completed only in 43 of thetotal of 75 districts. Of 37 districts, it was revealed that33 were LF-endemic. The ICT estimated prevalence inendemic areas ranges from 1% to 39.8%. The remaining32 districts still need to be epidemiologically mapped.The first round of MDA using albendazole plus DECbegan in 2003 in one IU, Parsa district: 508 534 peoplewere targeted with a reported coverage of 81.2%.In 2003, 3200 drug distributors were trained and 160people participated in training in disability alleviation.The LF elimination programme is implemented by theministry of health. WHO provided financial support tocover the operational costs in the district of Parsa only.No financial and technical support was provided forother districts. GSK donates albendazole to cover the fullat-risk population. Future partnership initiatives are yetto be identified, such as with USAID.Chapter 3 Programme implementationTable 3.31 Goal: to eliminate LF from Nepal by 2008Objectives• To interrupt LF transmission• To prevent LF-associated disabilityStrategies• Treating the entire at-risk population with a single administration of twodrugs — albendazole plus DEC — given together once a year for five years• New, simple techniques that are easily carried out at home: regularwashing with soap and water, regular exercising of the limbs, and othersimple activities
Page 1 and 2:
For further information about lymph
Page 3:
WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8:
3Report of the Technical Advisory G
Page 9 and 10:
P R O G R A M M E H I G H L I G H T
Page 11:
I N T R O D U C T I O N7This Annual
Page 14 and 15:
10Annual Report on Lymphatic Filari
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
38Figure 3.2 Outcomes and planning
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 59 and 60:
UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62:
ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63:
59AMERICAN PROGRAMME REVIEWGROUPAt
Page 66 and 67: 62Figure 3.63 Outcomes and planning
Page 68 and 69: 64Annual Report on Lymphatic Filari
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 104 and 105: 100Annual Report on Lymphatic Filar
Page 118 and 119: 114Figure 3.196 Outcomes and planni
Page 127: C H A P T E R 6FURTHER DOCUMENTATIO
Page 135 and 136: ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138: 1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140: 1353.3 Interruption of transmission
Page 141 and 142: 1373.3.6a Report of MDA coverage by
Page 143 and 144: 1393.3.7 Surveys in sentinel sites
Page 145 and 146: 1413.3.10 Please attach a map of th
Page 147 and 148: 1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150: A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152: 147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154: 149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?